Cidara Therapeutics, Inc. - Common Stock (CDTX)
Frequently Asked Questions About Cidara Therapeutics, Inc. - Common Stock (CDTX)
How does Cidara contribute to public health?
Cidara contributes to public health by developing innovative treatments for serious fungal and viral infections, aiming to reduce morbidity and mortality rates associated with these diseases. By addressing the growing threat of drug-resistant infections, the company plays a vital role in improving patient outcomes and overall health.
How does Cidara Therapeutics measure success?
Cidara Therapeutics measures success through advancements in its clinical trials, regulatory approvals for its drug candidates, partnerships with other organizations, and ultimately, the ability to bring novel therapies to market that improve patient care and health outcomes.
How is Cidara funded?
Cidara is funded through a combination of public equity, private investments, partnerships, and grants. As a publicly traded company, it generates additional capital from the sale of its shares, while also exploring collaborations with larger pharmaceutical companies to advance its drug development.
Is Cidara Therapeutics a publicly traded company?
Yes, Cidara Therapeutics is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol 'CDTX'. This allows investors to participate in the company’s growth and development through the purchase of shares in the open market.
What are Cidara's lead product candidates?
Cidara's lead product candidates include rezafungin, an intravenous and once-weekly echinocandin being developed for the treatment of invasive fungal infections, and Cloudbreak, a proprietary drug development platform designed to create new antiviral therapies. These candidates target critical areas in the treatment of severe infections, representing potential advances over existing therapies.
What challenges does Cidara face in the biotechnology industry?
Cidara faces several challenges common to the biotechnology industry, including regulatory hurdles, the high cost of clinical trials, market competition, and the inherent risks associated with drug development. Successfully navigating these challenges is critical to bringing their therapies to market and achieving commercial viability.
What clinical trials is Cidara currently conducting?
Cidara is currently conducting clinical trials focused on rezafungin for various indications related to invasive fungal infections. These trials are crucial for evaluating the safety, efficacy, and dosage parameters necessary for regulatory submissions and eventual commercialization of their products.
What diseases does Cidara Therapeutics focus on?
Cidara Therapeutics primarily focuses on serious diseases caused by fungal and viral pathogens. This includes conditions such as candidemia, invasive candidiasis, and other life-threatening infections, especially those that are increasingly resistant to traditional therapies.
What does Cidara Therapeutics, Inc. do?
Cidara Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics for treating serious diseases, particularly those caused by fungal and viral pathogens. The company aims to address significant unmet medical needs with its unique drug development platform, leveraging its expertise in novel formulations and mechanisms of action to create best-in-class treatments.
What is the Cloudbreak platform?
The Cloudbreak platform is Cidara's proprietary drug development system aimed at creating long-acting antiviral therapies. By utilizing this platform, Cidara seeks to develop therapeutics that target a variety of viral infections, offering innovative treatment options to patients who currently have limited alternatives.
What is the significance of rezafungin?
Rezafungin is significant because it represents a novel approach to treating invasive fungal infections, with the potential for improved patient outcomes through its once-weekly dosing regimen. This can enhance patient compliance and reduce the burden on healthcare systems due to shorter hospital stays and less frequent administration.
What makes Cidara's approach to drug development unique?
Cidara's approach to drug development is unique due to its focus on long-acting therapeutics and innovative drug formulations, which aim to extend the duration of action and improve patient adherence. This forward-thinking methodology enables the company to address unmet needs in the treatment of challenging infections efficiently.
What partnerships does Cidara Therapeutics have?
Cidara Therapeutics has established various partnerships with leading pharmaceutical companies and research institutions. These collaborations are aimed at enhancing their research capabilities, expanding their pipelines, and accelerating the development of their drug candidates into clinical practice.
What should investors know about Cidara Therapeutics?
Investors should know that Cidara Therapeutics is focused on developing breakthrough therapies for serious infections, the company is engaged in active clinical trials, and it has a solid pipeline. Investors should also be aware of the risks associated with biotechnology investments, including market volatility and the long timelines often required for drug development.
When was Cidara Therapeutics founded?
Cidara Therapeutics was founded in 2012, and since then, it has focused on developing novel therapeutics to address the growing challenges posed by infectious diseases, particularly those resistant to current treatment options.
Where can I find more information about Cidara Therapeutics?
More information about Cidara Therapeutics can be found on its official website, where the company provides updates on clinical trials, product pipelines, investor relations, and press releases. Additionally, the company’s filings with the U.S. Securities and Exchange Commission (SEC) offer detailed insights into its financial performance and strategic direction.
Where is Cidara Therapeutics headquartered?
Cidara Therapeutics is headquartered in San Diego, California. The location enables the company to tap into a rich biotechnology ecosystem, providing access to top talent and resources essential for advancing its research and development efforts.
Who are the key executives at Cidara Therapeutics?
The key executives at Cidara Therapeutics include the CEO, who leads the overall strategy and vision for the company, along with other leaders in research and development, finance, and operations. Their combined experience in biotechnology and pharmaceuticals drives the company toward successful drug development.
What is the current price of Cidara Therapeutics, Inc. - Common Stock?
The current price of Cidara Therapeutics, Inc. - Common Stock is 113.05
When was Cidara Therapeutics, Inc. - Common Stock last traded?
The last trade of Cidara Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on October 10th, 2025
What is the market capitalization of Cidara Therapeutics, Inc. - Common Stock?
The market capitalization of Cidara Therapeutics, Inc. - Common Stock is 5.60B
How many shares of Cidara Therapeutics, Inc. - Common Stock are outstanding?
Cidara Therapeutics, Inc. - Common Stock has 49.51M shares outstanding.